A Study Assessing Gallium-Labeled PSMA to Look for Signs of Prostate Cancer on PET/CT Scans after Radical Prostatectomy

Full Title

PSMA PET Imaging of Recurrent Prostate Cancer

Purpose

When PSA levels rise after the prostate has been removed, standard imaging methods are not highly effective for finding locations in the body where prostate cancer may have returned. In this study, researchers are assessing the use of a new imaging agent, gallium-labeled prostate-specific membrane antigen (PSMA), to use with positron emission tomography/computed tomography (PET/CT) scanning in men with a rising PSA after radical prostatectomy. The researchers believe this approach may yield more information about the location of prostate cancer in the body than standard imaging tests.

Patients’ PET/CT scans will be compared with standard MRI scans. If doctors find prostate cancer metastases, they will then use this information to create a treatment plan for the patient, such as radiation therapy.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a rising PSA level after prostatectomy.
  • Patients may not have previously received radiation therapy to the pelvic region nor be currently receiving hormonal therapy for prostate cancer recurrence.

For more information about this study and to inquire about eligibility, please contact Dr. Heiko Schoder at 212-639-7373.

Protocol

16-306

Phase

II

Disease Status

Relapsed or Refractory

Investigator